Overview
- Zydus Lifesciences reported Q2 FY26 revenue of Rs 6,123 crore and net profit of about Rs 1,259 crore, up 38% year on year.
- Zydus’ growth was led by US formulations revenue of Rs 2,744 crore (up roughly 13% YoY) and India formulations revenue of Rs 1,593 crore (up 8%).
- Zydus’ board approved raising up to Rs 5,000 crore via securities, and the company completed 100% ownership of Amplitude Surgical and acquired UK-based Comfort Click.
- Divi’s Laboratories posted Q2 revenue of Rs 2,715 crore (up 16% YoY) and net profit of Rs 689 crore (up 35%), supported by foreign exchange gains of Rs 63 crore.
- Shares fell despite the results, with Zydus down about 3% on the BSE and Divi’s off nearly 4%.